🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Can cardiac myosin inhibition alter adverse ECG changes associated with HCM? Check out our newly published case report! 🫀 Nosheen Reza, MD, MS Anjali Owens @deFeriaMD jacc.org/doi/10.1016/j.…

#HCM prime time Anjali Owens ❤️ Both #KnowFH and #HCM are 2 most frequent #monogenic AD conditions with the prevalence ~1:250 Timely Recognition Awareness Diagnosis Treatment

HCM outcomes at WisconsinACC. Thanks to Anjali Owens and Patrycja Galazka for reviewing diagnosis, imaging, and management of HCM. @4hcm Abdul Jamil Tajik @MattPetersMD Asad Ghafoor M.D. M.S. American Society of Echocardiography Heart_SCCT SCMR Abhinav Sharma Nicole Lohr, MD, PhD

Global remodeling on aficamten vs placebo - an analysis from #SEQUOIA #HCM by Anjali Owens presented at Hypertrophic Cardiomyopathy Medical Society #CardioTwitter

In this new #JACCCaseReports Clinical Vignette Corner, Dr. Melissa Austin, MD, et al discuss a case of a 60 y/o man w/ #cvHCM treated with the novel cardiac myosin inhibitor, mavacamten bit.ly/4gXqtKj Nosheen Reza, MD, MS Anjali Owens

HCM exercise dilemma: balancing benefits and risks. This FREE webinar delves into a real HCM case & shared decision-making for exercise plans. Learn to assess risk & personalize recommendations. Watch here: shorturl.at/MrPnB #HCM #Cardiovascular #ClinicalDecisionMaking

Don't miss out! ⏱️ Free 1-hour on-demand webinar recording on recognizing HCM in primary care. 🩺Learn about symptoms, exam findings & when to refer. Watch now: bit.ly/3zK9NF7 #Cardiology #PrimaryCare #HCM

#CircAHA24 VALOR-HCM demonstrates sufficient and sustained long-term improvement in obstructive HCM patients to avoid septal reduction therapy. Milind Desai MD MBA Neal Lakdawala Andrew Wang Anjali Owens @S2beri David Fermin, MD ahajrnls.org/3ZfwThe

New effort to improve care for hidden heart disease - American Heart Association initiative aims to overcome gaps in care for hypertrophic cardiomyopathy, the most common inherited heart disease. spr.ly/6014tCX8A

Low penetrance sarcomere variants (LowSVs) contribute to mild HCM alone but increase severity with high-risk variants. Neal Lakdawala James Ware Anjali Owens A/Prof Jodie Ingles @S2beri @sday_hcm Sean Zheng Adam Helms ahajournals.org/doi/abs/10.116…

🔬New in JACC Journals: HCM diagnosis criteria show unexpected demographic bias. Study of 50,000+ hearts reveals current thresholds create 8:1 male-female ratio Proposing demographic-adjusted thresholds to improve diagnosis🫀 authors.elsevier.com/a/1kPE52d9GH~T… UCL Institute of Cardiovascular Science Barts Health

Achieving Next-Level #HCM Care & Outcomes With Cardiac Myosin Inhibition: Better understand the current evidence & guidelines for CMIs within patient-centered care w/ Drs. Milind Desai & Anjali Owens. March 29 at 6:15 AM CDT. bit.ly/25HCMT #ACC25 #Cardiology PeerView

📅 The A Coruña Hypertrophic Cardiomyopathy Congress is Back! 🗓 September 18-19, 2025 🔬 Experts from 🇦🇷 🇦🇺 🇩🇪 🇪🇸 🇫🇷 🇬🇧 🇮🇹 🇳🇱 🇵🇹 🇺🇸 Sección Cardiopatías Familiares y Genética CV SEC Soc Esp Cardiología 🔗 hypertrophiccardiomyopathyacoruna.com/topics/

Remember to join us Saturday, March 29, at 6:15 AM CDT, for our #HCM live in-person & virtual symposium. Please tweet your questions in advance and follow PeerView for more #MedEd content! bit.ly/25HCMT #ACC25 Mended Hearts Anjali Owens

🛫PVI on the Go: Headed to Chicago for #ACC25? So are we! Kick off your day with Milind Desai MD MBA & Anjali Owens in an early morning dive into next-level #HCM care with CMIs. Sat, Mar 29 | 6:45–7:45 AM CDT Join us in-person or virtually: bit.ly/25HCMT Mended Hearts

Long-term (128 week) data on favorable cardiac remodeling in symptomatic ohcm on mavacamten from VALOR-HCM showing sustained improvements in LV mass, LV thickness, diastolic function, LV strain, LAVI, LA strain. In addition to LVOT gradients, symptoms and QoL. #ACC2025

Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients... sciencedirect.com/science/articl… Similar positive benefits of mavacamten in both sexes over 128 weeks in #oHCM pts as part of VALOR-HCM. Abstract presented at #ACC2025 with simult publication in #JACCheartfailure.

Women cardiologists, ready to lead in cardiomyopathies? 💪 CLIMB 2025 dives into rare & complex conditions with expert-led, interactive learning. 📅 Applications open May 1! 🔗 Learn more: womenasone.org/CLIMB2025 #CLIMB2025 #CardioTwitter #WIC

Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study W. H. Wilson Tang, MD Mark Drazner Anjali Owens Palak Shah Daniel D. Kinnamon, PhD @markhofmeyer Jane Wilcox, MD, MSc Elizabeth Jordan #AHAJournals ahajrnls.org/4lAS6Ln

🔥 HOT #HeartFailure2025 #CIRRUS­HCM Cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy: 📌 exciting new therapeutic option for both oHM 📌 well tolerated without meaningful impact on LVEF 📌 improve LVOT-G, NT-proBNP, e', KCCQ, and NYHA European Society of Cardiology Anjali Owens